NCT06823375 2026-03-04
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
Chinese University of Hong Kong
Phase 2 Recruiting
Clinical Trials
8 trialsNCT06844357 2025-04-06
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Zhejiang Raygene Pharmaceuticals Co., Ltd
Phase 2/3 Recruiting
NCT05873244 2025-03-21
CXD101 in Immunotherapy-related Liver Cancer
Chinese University of Hong Kong
Phase 2 Recruiting
NCT06766773 2025-01-10
CWSRIH-HCC
The First People's Hospital of Neijiang
Phase NA Active not recruiting
NCT06463444 2024-06-17
Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models
Tongji Hospital
Phase 1 Recruiting
NCT06413017 2024-05-14
Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT04123340 2023-01-06
IAMCOMPLETE
Leiden University Medical Center
Phase 2 Completed
NCT01470495 2017-03-28
REPEAT
Southwest Hospital, China
Phase NA Unknown